Skip to content
Atlas Research Compounds

Immune signaling

Thymosin Alpha 1

A thymic peptide with a substantial immune-signaling literature.

Evidence
Mixed translational
Literature
Preclinical and clinical literature
Family
Thymic immune-signaling peptide

Overview

Thymosin alpha 1 has been studied across innate and adaptive immune contexts and has a broader clinical literature than most entries in this catalog. Interpretation still depends on indication, jurisdiction, study design, and treatment context.

Evidence maturity

Evidence score4/5

Substantial clinical evidence

The score summarizes evidence maturity, not safety, effectiveness, or suitability for any use.

Mechanism summary

Investigated in innate and adaptive immune signaling across preclinical and clinical contexts.

Research category
Recovery Research
Editorial status
Published

Evidence synthesis

Structured evidence summary

Human studies
11
Animal studies
0
In vitro records
2
Review records
11
Abstract extracted
6
Metadata verified
14

Evidence strength

Moderate translational

Confidence

Moderate confidence

Major findings

  • The verified set includes clinical, review, and synthesis records across sepsis, COVID-era immune studies, pancreatitis, hepatitis B, HIV, oncology, and immune-modulation contexts.
  • TA1 has the strongest human-study footprint among the Phase 4 authority compounds.

Major limitations

  • Evidence is indication-specific and cannot be collapsed into one immune-function conclusion.
  • Conflicting or context-dependent safety and outcome interpretation remains flagged for editorial review.

Counts are generated from verified PubMed records. Findings above are evidence-map observations, not clinical recommendations or inferred study outcomes. See the scoring methodology.

Scoring methodology

Evidence strength, quality, and confidence

Evidence strength

Compound-level strength is based on the verified study mix: human records, animal records, review or synthesis records, and extraction depth. It describes evidence maturity only.

Study quality

Study-level quality is not assessed for metadata-only records. Abstract-extracted records are rated from study design and extraction depth, not from unreviewed full-text claims.

Confidence

Confidence is capped when records remain metadata verified. Atlas does not raise confidence by counting citations without extracting endpoints, comparators, duration, and limitations.

Workflow states are `METADATA_VERIFIED`, `ABSTRACT_EXTRACTED`, `FULLTEXT_REVIEWED`, and `EDITORIAL_APPROVED`. Because full-text review is not available in this phase, no study is promoted to full-text or editorial-approved status.

Research timeline

Evidence stages describe maturity, not a chronological promise of development.

  1. Identity and target

    Documented

    The compound identity or proposed target is described in research literature.

  2. Preclinical research

    Documented

    Laboratory or animal research forms part of the evidence base.

  3. Human research

    Documented

    Multiple human studies or an established clinical literature are available.

  4. Independent synthesis

    Emerging

    Independent replication and synthesis remain important evidence gaps.

Open research questions

  1. 01Which immunological effects are context-dependent?
  2. 02How do outcomes vary across indications and study designs?
  3. 03Which biomarkers best reflect target engagement?

Literature starting points

These links support further review; inclusion is not an endorsement of every indexed conclusion.

  1. 01

    Thymosin alpha 1 literature index

    PubMed, U.S. National Library of Medicine · Database

    Open source
  2. 02

    Atlas internal research database

    Internal Research Database · 2026 · Database

    Open source

Phase 2 study database

20 verified publications

Search all studies →
2025Thymosin alpha 1 alleviates inflammation and prevents infection in patients with severe acute pancreatitis through immune regulation: a systematic review and meta-analysisGrade A2025Aging and Thymosin Alpha-1.Grade D2025The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double-blinded, randomised, placebo-controlled, phase 3 trial.Grade A2023The efficacy of thymosin alpha-1 therapy in moderate to critical COVID-19 patients: a systematic review, meta-analysis, and meta-regressionGrade A2023A Pilot Trial of Thymalfasin (Thymosin-α-1) to Treat Hospitalized Patients With Hypoxemia and Lymphocytopenia Due to Coronavirus Disease 2019 Infection.Grade A

Deep research cluster

Explore Thymosin Alpha 1 by evidence question

MechanismMechanistic pathways reported in verified publications, separated from clinical inference.Human studiesVerified human publications, study designs, findings, and explicit limitations.Animal studiesPreclinical animal models and the boundaries on translating their results.Safety evidenceWhat the verified publication set can and cannot establish about safety.Research historyA publication timeline built only from verified study records.ComparisonsContextual links to related compounds and existing structured comparisons.

Related comparisons

TA1 vs. ThymulinGHK-Cu vs. TA1BPC-157 vs. TA1TB-500 vs. TA1TA1 vs. SelankTA1 vs. NAD+TA1 vs. SS-31SS-31 vs. TA1

Continue the research map

Related content

CompoundThymulinCompoundGHK-CuCompoundBPC-157Verified studyThymosin alpha 1 alleviates inflammation and prevents infection in patients with severe acute pancreatitis through immune regulation: a systematic review and meta-analysisVerified studyAging and Thymosin Alpha-1.Verified studyThe efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double-blinded, randomised, placebo-controlled, phase 3 trial.ComparisonTA1 vs. ThymulinComparisonGHK-Cu vs. TA1ComparisonBPC-157 vs. TA1ComparisonTB-500 vs. TA1ComparisonTA1 vs. SelankComparisonTA1 vs. NAD+ComparisonTA1 vs. SS-31ComparisonSS-31 vs. TA1Topic hubRecoveryTopic hubImmune FunctionTopic hubPeptide Research